Cargando…

Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma

Lenvatinib is a first-line standard treatment for advanced hepatocellular carcinoma (HCC) with better anti-tumor effects than sorafenib, as shown by greater inhibition of the kinases of fibroblast growth factor receptor and vascular endothelial growth factor (VEGF) receptor. This report describes a...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Naomi, Tajiri, Kazuto, Futsukaichi, Yuka, Tanaka, Shinichi, Murayama, Aiko, Entani, Toshiki, Kobayashi, Saito, Takahashi, Kosuke, Fujii, Tsutomu, Imura, Johji, Yasuda, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036537/
https://www.ncbi.nlm.nih.gov/pubmed/32110202
http://dx.doi.org/10.1159/000505774
_version_ 1783500238257913856
author Suzuki, Naomi
Tajiri, Kazuto
Futsukaichi, Yuka
Tanaka, Shinichi
Murayama, Aiko
Entani, Toshiki
Kobayashi, Saito
Takahashi, Kosuke
Fujii, Tsutomu
Imura, Johji
Yasuda, Ichiro
author_facet Suzuki, Naomi
Tajiri, Kazuto
Futsukaichi, Yuka
Tanaka, Shinichi
Murayama, Aiko
Entani, Toshiki
Kobayashi, Saito
Takahashi, Kosuke
Fujii, Tsutomu
Imura, Johji
Yasuda, Ichiro
author_sort Suzuki, Naomi
collection PubMed
description Lenvatinib is a first-line standard treatment for advanced hepatocellular carcinoma (HCC) with better anti-tumor effects than sorafenib, as shown by greater inhibition of the kinases of fibroblast growth factor receptor and vascular endothelial growth factor (VEGF) receptor. This report describes a patient with advanced HCC who experienced perforation of the small intestine 1 month after starting the treatment with lenvatinib. This patient likely had partial necrosis of a metastasis to the small intestine before starting lenvatinib treatment, with subsequent ischemic changes leading to perforation of the small intestine. Although metastasis of HCC to the small intestine is rare, patients with these metastases should be regarded as being at risk for perforation during lenvatinib treatment.
format Online
Article
Text
id pubmed-7036537
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-70365372020-02-27 Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma Suzuki, Naomi Tajiri, Kazuto Futsukaichi, Yuka Tanaka, Shinichi Murayama, Aiko Entani, Toshiki Kobayashi, Saito Takahashi, Kosuke Fujii, Tsutomu Imura, Johji Yasuda, Ichiro Case Rep Gastroenterol Single Case Lenvatinib is a first-line standard treatment for advanced hepatocellular carcinoma (HCC) with better anti-tumor effects than sorafenib, as shown by greater inhibition of the kinases of fibroblast growth factor receptor and vascular endothelial growth factor (VEGF) receptor. This report describes a patient with advanced HCC who experienced perforation of the small intestine 1 month after starting the treatment with lenvatinib. This patient likely had partial necrosis of a metastasis to the small intestine before starting lenvatinib treatment, with subsequent ischemic changes leading to perforation of the small intestine. Although metastasis of HCC to the small intestine is rare, patients with these metastases should be regarded as being at risk for perforation during lenvatinib treatment. S. Karger AG 2020-02-05 /pmc/articles/PMC7036537/ /pubmed/32110202 http://dx.doi.org/10.1159/000505774 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case
Suzuki, Naomi
Tajiri, Kazuto
Futsukaichi, Yuka
Tanaka, Shinichi
Murayama, Aiko
Entani, Toshiki
Kobayashi, Saito
Takahashi, Kosuke
Fujii, Tsutomu
Imura, Johji
Yasuda, Ichiro
Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
title Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
title_full Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
title_fullStr Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
title_full_unstemmed Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
title_short Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
title_sort perforation of the small intestine after introduction of lenvatinib in a patient with advanced hepatocellular carcinoma
topic Single Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036537/
https://www.ncbi.nlm.nih.gov/pubmed/32110202
http://dx.doi.org/10.1159/000505774
work_keys_str_mv AT suzukinaomi perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma
AT tajirikazuto perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma
AT futsukaichiyuka perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma
AT tanakashinichi perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma
AT murayamaaiko perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma
AT entanitoshiki perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma
AT kobayashisaito perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma
AT takahashikosuke perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma
AT fujiitsutomu perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma
AT imurajohji perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma
AT yasudaichiro perforationofthesmallintestineafterintroductionoflenvatinibinapatientwithadvancedhepatocellularcarcinoma